The Medical and Surgical Practice of NaProTECHNOLOGY, 413-424, 2004
Abstract
Chapter 34 of Hilgers (2004) examines how NaProTechnology cycle charting may identify women at elevated risk for three gynecologic cancers: endometrial, breast, and ovarian. The chapter presents clinical case series and a small prospective study suggesting that observable cycle biomarkers, particularly patterns indicating suboptimal luteal-phase function, may precede diagnosis and could inform earlier evaluation, while calling explicitly for further research to validate these findings.
Topics
Women's Health > Gynecologic Oncology > Endometrial Cancer Risk and DetectionWomen's Health > Gynecologic Oncology > Breast Cancer Hormonal AssociationsWomen's Health > Gynecologic Oncology > Ovarian Cancer Early DetectionNaProTECHNOLOGY > Cycle Charting > Biomarker IdentificationMenstrual Cycle > Luteal Phase > Progesterone DeficiencyWomen's Health > Body Literacy > Cycle-Based Risk StratificationNaProTECHNOLOGY > Clinical Applications > Cancer Surveillance Hypothesis
Cite this article
Hilgers, T. W. (2004). Chapter 34: Cancer: NaProTECHNOLOGY and Early Detection. *The Medical and Surgical Practice of NaProTECHNOLOGY*, 413-424.
Hilgers TW. Chapter 34: Cancer: NaProTECHNOLOGY and Early Detection. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:413-424.